Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Prelude Therapeutics
Biotech
Prelude thinks SMARCA with AbCellera deal, culls 2 candidates
Confident in the potential of its SMARCA2 degrader and CDK9 inhibitor to treat cancer, Prelude is scrapping the other half of its clinical pipeline.
James Waldron
Nov 2, 2023 8:06am
3 more biotechs look to cull, partner assets
Nov 14, 2022 11:40am
Teon poaches Janssen US oncology head—Chutes & Ladders
Mar 11, 2022 9:30am
BeiGene's hematology CMO jumps to Prelude
Mar 9, 2022 11:08am
Oncology biotech Prelude guns for $100M IPO
Sep 8, 2020 10:14am
Novartis says hello to new pharma chief—Chutes & Ladders
Jun 14, 2019 9:00am
